Treatments · 97 clinics in 9 countries · checked 21 Oct 2026
Hormone therapy: evidence, regulation and where it is offered
Hormone therapy replaces or adds hormones such as oestrogen, progesterone or testosterone, and is a prescription treatment. Our evidence label for it is Depends on use. Established for some medical conditions, unproven as a longevity treatment. 97 clinics we list offer it, in the United States, the United Kingdom, Germany, Spain, Indonesia, Thailand, Australia, the United Arab Emirates and Mexico.
What the evidence says
Prescription status: a prescription-only treatment. We show no prices for it where the rules forbid advertising prescription medicines.
Hormone therapy is an established treatment for some conditions. In the UK, the National Institute for Health and Care Excellence (NICE) recommends offering hormone replacement therapy (HRT) for hot flushes and night sweats around the menopause, after talking through the benefits and risks (NICE guideline NG23). In the US, menopause hormone products are approved for moderate to severe hot flushes, vaginal dryness and preventing bone loss (FDA, February 2026).
For men, the Endocrine Society says low testosterone should be diagnosed only when a man has symptoms and clearly and consistently low levels. It recommends against routinely prescribing testosterone to all men aged 65 or over with low levels (Endocrine Society, 2018).
None of these guidelines or approvals is for slowing ageing.
Regulators and prescription status
United States. The US Food and Drug Administration (FDA) approves testosterone only for men with low testosterone linked to a medical condition. In February 2025 it kept a limit on its use for low testosterone due to ageing, and added warnings about raised blood pressure (FDA, 2025). In February 2026 it removed statements on heart disease, breast cancer and probable dementia from the boxed warning of six menopause hormone products.
Depends on use means: Established for some medical conditions, unproven as a longevity treatment.
What regulators say
| Country | Note | Source |
|---|---|---|
| United States | Testosterone products are not approved for low testosterone caused by ageing alone; the FDA kept this limitation in its 2025 labelling update. | FDA, 28 February 2025 |
| United Kingdom | No regulator statement recorded yet. | |
| Germany | No regulator statement recorded yet. | |
| Spain | No regulator statement recorded yet. | |
| Indonesia | No regulator statement recorded yet. | |
| Thailand | No regulator statement recorded yet. | |
| Australia | No regulator statement recorded yet. | |
| United Arab Emirates | No regulator statement recorded yet. | |
| Mexico | No regulator statement recorded yet. | |
Where it is offered
- Longevium Jumeirah 3
- Longevium JVC
- DNA Health Dubai Marina
- DNA Health Downtown Dubai
- OMICS Precision Health
- DNA Health Alserkal Avenue
- DNA Health & Wellness DIFC
- DNA Health & Wellness Al Wasl
- Shookra Business Bay
- Next Health Dubai
- Shookra Andaz Dubai The Palm
- Dr Felix Happich Longevity Medicine
- EV Clinic Dubai
- Al Das Longevity Clinic
- Yutopia Clinic
- Revitalife Clinic
- King's College Hospital Dubai Longevity Clinic
- SuperiorMed Palm Jumeirah
Published prices
Prices are not shown in the United Kingdom, Germany, Spain, Indonesia, Thailand, Australia, the United Arab Emirates and Mexico: it is a prescription-only treatment there.
No price that may be shown is published by the clinics we list.
Safety and questions to ask
NICE says HRT with oestrogen alone makes little or no difference to the risk of breast cancer. HRT that combines oestrogen with a progestogen can raise the risk, depending on how long it is taken, and the risk falls after it stops. HRT tablets raise the risk of blood clots; patches and gels at standard doses do not. Testosterone can raise blood pressure.
- Will a doctor who can prescribe see me and test my hormone levels first?
- What is the treatment for, and how will we know if it works?
- Is the product a licensed medicine, or made up by a pharmacy?
- What are the risks for me, and how often will I have follow-up tests?
- Will my own doctor be told?
Sources
- National Institute for Health and Care Excellence: menopause guideline NG23, recommendations
- US Food and Drug Administration: FDA approves labeling changes to menopausal hormone therapy products, 12 February 2026
- Endocrine Society: experts issue recommendations to improve testosterone prescribing practices, 17 March 2018
- US Food and Drug Administration: FDA issues class-wide labeling changes for testosterone products, 28 February 2025